Page 16 - 10 Most Trusted Diagnostic Companies in India 2022
P. 16
COVER STORY
We initially started from a normal are into the production of prefin- Most of the Pharma companies
pallet product to now having PFIs ished formulation intermediates as the manufacturing units and
which are available in the range of but the world still comes to us. their progression is limited to the
100 nanometers. We have enhanced Reasons? Our dexterity in instructions given by someone
and upgraded our encapsulation developing innovative technolo- else. Whereas at MKPPL, develop-
techniques. All our visions and gies. We developed products at ment is a Mantra. All our products
plans are being reflected well in our regulatory compliance and we follow a very rigorous R&D system.
products which are appreciated serve the world under the Make The core of MKPPL is its R&D
worldwide by leading companies. in India vision wherein we manu- Department. For us, it is manufac-
Our ability to encapsulate even facture and develop products turing with an R&D background and
the most hydrophobic and hydro- at our facility and supply them
VISION philic drugs through liposomal, to the rest of the world. This we don’t do what is called manufac-
turing developments. We do not
“To become a successful polymeric and various other kinds speaks for our unique character. always follow what everybody else
of encapsulation polymers which
regulatory compliant prefinis- Most of the manufacturing units is manufacturing; we try to make a
we used to produce notable prod-
hed formulation intermediate ucts has become our specialty. in the country follow the typical good product better and a better
facility was the vision which So the vision has moved from prefinished formulation interme- product the best and that is what
diates such as proton pump inhib-
we had 17 years ago. Even just being a company that‘s into itors of immune suppressants or differentiates us from the list of
prefinished formulation inter- manufacturers in the country.
today the vision continues mediates to a company that other anti-infectives or anti-in-
but it has branched into not delivers final products with a flammatories. Whereas at MKP, we
just being a PFI product promise of a painless relief expe- have tried to foray ourselves into
rience at a cost-effective model. those paths which are relatively
company, but to be a finished unknown; we walk where the rest
dosage firm based on an FTF WHAT ARE THE CHARACTER- don’t. We do those developments
ISTICS THAT DIFFERENTIATE that very few people dare to do
formulation as well.” And
MURLI KRISHNA PHARMA? so. Our R&D is also approved by
that’s just the iceberg! We are I am often encountered with this the Department of Scientific and
growing strong in Nanoparticles question and queries like what Industrial Research (DSIR). We
manufacturing as well. This is it that differentiates MKPPL do a lot of advancements not
from the rest of the companies? only for ourselves but including
is the vision we are eyeing for I’d like to answer differently; countries like the USA and Europe
MKPPL in the near future. numerous Indigenous companies as well.
|16 thecorporatereview.com | India | Vol. 3 | Issue 3 | March 2022 |17
